Origin Genomics founder calls embryo editing moral imperative

We are told this is a matter of moral nerve: Cathy Tie of Origin Genomics says editing the genes of human embryos is a “moral imperative,” and the critics answer that it is reckless, that no family’s hope justifies a permanent experiment on a person who cannot consent. But state it as a design problem. The need is a child born without the hereditary disease the parents carry. The resources already in the system are an in-vitro fertilization laboratory, a clutch of embryos, and a sequencing machine. The real constraint is precision: how to secure the healthy outcome while touching the fewest molecules. A different question appears: what arrangement meets the need with less?

Look at what the clinic already does. When parents carry a known single-gene disease, IVF produces several embryos. A few cells are sampled from each, read, and the unaffected embryo is transferred. Nothing is cut. Nothing is rewritten. The function Origin Genomics proposes to perform with molecular scissors is, in most families, already performed by reading and choosing. That is the direction every mature technology travels, from the telegraph cable to the radio wave: the same result, less material intervention. Germline editing, offered to those families, is a step backward, a heavier tool reaching for a job a lighter one already finishes.

Here I must meet the strongest version of Tie’s case, because it is real. There are couples for whom selection offers nothing: a parent with two copies of a dominant disease gene, or two parents who both have the same recessive condition. Every embryo they can make is affected. For them there is no healthy embryo to choose, and only a correction will do. That is a genuine specification, and I will not pretend it away. But notice its size. It is a narrow band of families, rare by any honest count. A “moral imperative” issued to the whole species, resting on a slender clinical case, is a structure whose load claims run far beyond its members.

And the members are weak. Editing a single-cell embryo can cut in the wrong place, and it can leave a mosaic: some cells corrected, some not, some altered in ways no one intended. Selection’s failure is a misread test. Editing’s failure is a child, and a lineage, carrying an error written by hand. When one arrangement’s worst case is a disappointment and the other’s is an heirloom, the design comparison is not close.

So why does a company lead with the heavy tool? Here the design frame runs out, and I will say so plainly. Reading and choosing embryos is established practice, sold by many clinics, hard to own. An edit is a product. Investors do not fund a startup to recommend the method already on the shelf. The phrase “moral imperative” does engineering work of its own: it converts a narrow, risky service into a universal duty, and a duty has a much larger market than a rare-case therapy. That is not a scientific dispute. It is a question of who profits from which arrangement, and no clever protocol will settle it. Regulators, clinics, and the public will settle it, or fail to.

There is a picture that says the whole thing. A couple sits in a genetic counselor’s office. The counselor turns a screen toward them showing five embryos, three marked clear. The wife starts to cry, relieved. In the next room, a founder rehearses a pitch about rewriting the human genome to save that very couple, who have just been saved by a spreadsheet.

The real waste in this system is not biological. It is that screening remains expensive and unevenly insured, so the families who could use the light tool are often priced out of it, and are then offered the heavy one as rescue. Redirect the capital now chasing germline edits toward cheaper IVF and broader carrier testing, before pregnancy, and the number of children born with these diseases falls without a single cut. Reserve editing research for the truly unselectable cases, under the slow and public scrutiny that permanence demands.

What This Means For You: A company calling its own product a moral imperative has told you its market strategy, not its ethics. Coverage that omits embryo screening is presenting a choice between editing and suffering that most families never actually face.

The scissors are impressive. For most of these families, the magnifying glass already finished the job.